Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CEMPRA, INC. (MLNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/24/2020 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/24/2020 GN Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
06/12/2020 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
06/09/2020 GN Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
04/20/2020 S-3DPOS Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020 S-3DPOS Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020 S-3DPOS Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020 S-3DPOS Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020 S-3DPOS Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/20/2020 8-K Bankruptcy or Receivership, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Ch...
Docs: "Restated Certificate of Incorporation of Melinta Therapeutics, Inc",
"Amended and Restated By-Laws of Melinta Therapeutics, Inc",
"Press Release"
04/14/2020 8-K Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Confirmation Order",
"Balance Sheet included in the February Monthly Operating Report for the Period of February 1, 2020 through February 29, 2020, as filed with the United States Bankruptcy Court for the District of Delaware on March 30, 2020"
03/04/2020 GN Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
02/14/2020 8-K Quarterly results
02/13/2020 GN Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
02/05/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
01/08/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Docs: "FORM 8-K"
12/27/2019 8-K Quarterly results
12/27/2019 GN Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
11/12/2019 GN Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
11/12/2019 10-Q Quarterly Report for the period ended September 30, 2019
11/06/2019 8-K Other Events
10/24/2019 8-K Quarterly results
09/03/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Separation and Release Agreement, between Melinta Therapeutics, Inc. and John H. Johnson",
"Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director MORRISTOWN, N.J., September 3, 2019 - Melinta Therapeutics, Inc. , a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer's appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors. Jennifer is also an ideal addition to Melinta's board of directors and we are pleased that th..."
08/12/2019 SC 13D/A Vatera Healthcare Partners LLC reports a 55.1% stake in Melinta Therapeutics, Inc.
08/09/2019 10-Q Quarterly Report for the period ended June 30, 2019
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy